{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T07:47:06Z","timestamp":1791013626148,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2007,9,12]],"date-time":"2007-09-12T00:00:00Z","timestamp":1189555200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1007\/s00280-007-0584-7","type":"journal-article","created":{"date-parts":[[2007,9,11]],"date-time":"2007-09-11T06:57:36Z","timestamp":1189493856000},"page":"349-354","source":"Crossref","is-referenced-by-count":25,"title":["Successful amelioration of oxaliplatin-induced hyperexcitability syndrome with the antiepileptic pregabalin in a patient with pancreatic cancer"],"prefix":"10.1007","volume":"61","author":[{"given":"Muhammad Wasif","family":"Saif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrukh","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,9,12]]},"reference":[{"key":"584_CR1","unstructured":"Package insert. Eloxatin (oxaliplatin). Sanofi-Synthelabo, New York, July 2004"},{"key":"584_CR2","first-page":"32","volume":"25","author":"H Bleiberg","year":"1998","unstructured":"Bleiberg H, de Gramont A (1998) Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer. Semin Oncol 25:32\u201339","journal-title":"Semin Oncol"},{"key":"584_CR3","first-page":"23","volume":"25","author":"Y Becouarn","year":"1998","unstructured":"Becouarn Y, Rougier P (1998) Clinical efficacy of oxaliplatin monotherapy: phase II trials in advanced colorectal cancer. Semin Oncol 25:23\u201331","journal-title":"Semin Oncol"},{"key":"584_CR4","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","volume":"18","author":"A Gramont De","year":"2000","unstructured":"De Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938\u20132947","journal-title":"J Clin Oncol"},{"issue":"5 suppl 15","key":"584_CR5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1053\/sonc.2002.35525","volume":"29","author":"E Gamelin","year":"2002","unstructured":"Gamelin E, Gamelin L, Bossi L, Quasthoff S (2002) Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 29(5 suppl 15):21\u201333","journal-title":"Semin Oncol"},{"issue":"5","key":"584_CR6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1471-2407-5-116","volume":"16","author":"GD Leonard","year":"2005","unstructured":"Leonard GD, Wright MA, Quinn MG, Harold N, Schuler B, Thomas RR, Grem JL (2005) Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer 16(5):116","journal-title":"BMC Cancer"},{"issue":"3","key":"584_CR7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/mus.10559","volume":"29","author":"TJ Lehky","year":"2004","unstructured":"Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK (2004) Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 29(3):387\u2013392","journal-title":"Muscle Nerve"},{"key":"584_CR8","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1002\/mus.880171103","volume":"17","author":"RG Auger","year":"1994","unstructured":"Auger RG (1994) Diseases associated with excess motor unit activity. Muscle Nerve 17:1250\u20131263","journal-title":"Muscle Nerve"},{"key":"584_CR9","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/(SICI)1097-4598(200005)23:5<696::AID-MUS5>3.0.CO;2-W","volume":"23","author":"J Zielasek","year":"2000","unstructured":"Zielasek J, Martini R, Suter U et al (2000) Neuromyotonia in mice with hereditary myelinopathies. Muscle Nerve 23:696\u2013701","journal-title":"Muscle Nerve"},{"key":"584_CR10","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1136\/bmj.1.6176.1464","volume":"1","author":"J Reeback","year":"1979","unstructured":"Reeback J, Benton S, Swash M et al (1979) Penicillamine-induced neuromyotonia. BMJ 1:1464\u20131465","journal-title":"BMJ"},{"key":"584_CR11","first-page":"528","volume":"15","author":"PH Caldron","year":"1988","unstructured":"Caldron PH, Wilbourn AJ (1988) Gold neurotoxicity and myokymia. J Rheumatol 15:528\u2013529","journal-title":"J Rheumatol"},{"key":"584_CR12","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/brain\/117.2.225","volume":"117","author":"H Bostock","year":"1994","unstructured":"Bostock H, Burke D, Hales JP (1994) Differences in behaviour of sensory and motor axons following release of ischaemia. Brain 117:225\u2013234","journal-title":"Brain"},{"key":"584_CR13","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1093\/brain\/122.11.2057","volume":"122","author":"T Nagado","year":"1999","unstructured":"Nagado T, Arimura K, Sonoda Y et al (1999) Potassium current suppression in patients with peripheral nerve hyperexcitability. Brain 122:2057\u20132066","journal-title":"Brain"},{"key":"584_CR14","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/(SICI)1097-4598(199907)22:7<823::AID-MUS3>3.0.CO;2-1","volume":"22","author":"P Maddison","year":"1999","unstructured":"Maddison P, Newsom-Davis J, Mills KR (1999) Strength-duration properties of peripheral nerve in acquired neuromyotonia. Muscle Nerve 22:823\u2013830","journal-title":"Muscle Nerve"},{"key":"584_CR15","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ana.410410215","volume":"41","author":"IK Hart","year":"1997","unstructured":"Hart IK, Waters C, Vincent A et al (1997) Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Ann Neurol 41:238\u2013246","journal-title":"Ann Neurol"},{"key":"584_CR16","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/(SICI)1097-4598(200005)23:5<655::AID-MUS1>3.0.CO;2-E","volume":"23","author":"A Vincent","year":"2000","unstructured":"Vincent A (2000) Understanding neuromyotonia. Muscle Nerve 23:655\u2013657","journal-title":"Muscle Nerve"},{"key":"584_CR17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0002-9629(15)40732-3","volume":"319","author":"IK Hart","year":"2000","unstructured":"Hart IK (2000) Acquired neuromyotonia. A new autoantibody-mediated neuronal potassium channelopathy. Am J Med Sci 319:209\u2013216","journal-title":"Am J Med Sci"},{"issue":"7","key":"584_CR18","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1200\/JCO.2002.07.056","volume":"20","author":"RH Wilson","year":"2002","unstructured":"Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL (2002) Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 20(7):1767\u20131774","journal-title":"J Clin Oncol"},{"issue":"2","key":"584_CR19","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3816\/CCC.2006.n.032","volume":"6","author":"PL Mitchell","year":"2006","unstructured":"Mitchell PL, Goldstein D, Michael M, Beale P, Friedlander M, Zalcberg J, White S, Thomson JA, Clarke S (2006) Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. Clin Colorectal Cancer 6(2):146\u2013151","journal-title":"Clin Colorectal Cancer"},{"key":"584_CR20","first-page":"609","volume":"19","author":"G Mariani","year":"2000","unstructured":"Mariani G, Garrone O, Granetto C et al (2000) Oxaliplatin-induced neuropathy: could gabapentin be the answer. Proc Am Soc Clin Oncol 19:609, (abstract 2397)","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"1\u20132","key":"584_CR21","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0304-3959(03)00173-8","volume":"105","author":"JC Fehrenbacher","year":"2003","unstructured":"Fehrenbacher JC, Taylor CP, Vasko MR (2003) Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 105(1\u20132):133\u2013141","journal-title":"Pain"},{"issue":"1","key":"584_CR22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003495-200565010-00011","volume":"65","author":"JE Frampton","year":"2005","unstructured":"Frampton JE, Foster RH (2005) Pregabalin in the treatment of postherpetic neuralgia. Drugs 65(1):111\u2013120","journal-title":"Drugs"},{"issue":"3","key":"584_CR23","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.pain.2005.02.032","volume":"115","author":"R Freynhagen","year":"2005","unstructured":"Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M (2005) Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of fble- and fixed-dose regimens. Pain 115(3):254\u2013263","journal-title":"Pain"},{"key":"584_CR24","unstructured":"Wesche D, Bockbrader H (2005) A pharmacokinetic comparison of pregabalin and gabapentin. http:\/\/www.ampainsoc.org\/abstract\/2005\/data\/684\/index.html . Accessed 22 June"},{"key":"584_CR25","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/mus.1078","volume":"24","author":"H Lahrmann","year":"2001","unstructured":"Lahrmann H, Albrecht G, Drlicek M, Oberndorfer S, Urbanits S, Wanschitz J et al (2001) Acquired neuromyotonia and peripheral neuropathy in a patient with Hodgkin\u2019s disease. Muscle Nerve 24:834\u2013838","journal-title":"Muscle Nerve"},{"key":"584_CR26","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1002\/mus.880171103","volume":"17","author":"RG Auger","year":"1994","unstructured":"Auger RG (1994) AAEM minimonograph #44: diseases associated with excess motor unit activity. Muscle Nerve 17:1250\u20131263","journal-title":"Muscle Nerve"},{"key":"584_CR27","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/ana.410380505","volume":"38","author":"P Shillito","year":"1995","unstructured":"Shillito P, Molenaar PC, Vincent A, Leys K, Zheng W, van den Berg RJ et al (1995) Acquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nerves. Ann Neurol 38:714\u2013722","journal-title":"Ann Neurol"},{"issue":"4","key":"584_CR28","first-page":"249","volume":"1","author":"MW Saif","year":"2005","unstructured":"Saif MW, Reardon J (2005) Management of oxaliplatin-induced peripheral neuropathy. Therap Clin Risk Manage 1(4):249\u2013248","journal-title":"Therap Clin Risk Manage"},{"key":"584_CR29","unstructured":"FDA approval letter of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy. Department of Health & Human Services. http:\/\/www.fda.gov\/cder\/foi\/appletter\/2004\/21446ltr.pdf"},{"issue":"12","key":"584_CR30","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1345\/aph.1G078","volume":"39","author":"B Shneker","year":"2005","unstructured":"Shneker B, McAuley JW (2005) Pregabalin: a new neuromodulator with broad therapeutic indications. Ann Pharmacother 39(12):2029\u20132037","journal-title":"Ann Pharmacother"},{"issue":"4","key":"584_CR31","first-page":"576","volume":"4","author":"MW Saif","year":"2004","unstructured":"Saif MW (2004) Oral calcium ameliorating oxaliplatin-induced peripheral neuropathy. J Appl Res 4(4):576\u2013582","journal-title":"J Appl Res"},{"key":"584_CR32","unstructured":"CONCEPT Comparison of oxaliplatin vs. conventional methods with calcium\/magnesium in first-line metastatic colorectal cancer. http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00129870 . Accessed 11 Aug 2007"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-007-0584-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-007-0584-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-007-0584-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T10:06:48Z","timestamp":1559038008000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-007-0584-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,12]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["584"],"URL":"https:\/\/doi.org\/10.1007\/s00280-007-0584-7","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9,12]]}}}